Related Experiment Videos
CGS 12970: a novel, long acting thromboxane synthetase inhibitor
Insights
CGS 12970 selectively inhibits thromboxane synthetase, reducing thromboxane B2 production in platelets and blood. This compound shows unique effects on thrombocytopenia, distinguishing it from other inhibitors.
Area of Science:
- Biochemistry
- Pharmacology
Background:
- Thromboxane synthetase plays a key role in platelet aggregation and thrombosis.
- Selective inhibitors of thromboxane synthetase are potential therapeutic agents for cardiovascular diseases.
Purpose of the Study:
- To investigate the pharmacological profile of CGS 12970 as a selective thromboxane synthetase inhibitor.
- To evaluate the effects of CGS 12970 on platelet function, blood clotting, and in vivo models of thrombosis and thrombocytopenia.
Main Methods:
- In vitro enzyme inhibition assays (IC50 determination).
- In vitro and ex vivo studies on human and animal platelet aggregation and thromboxane B2 production.
- In vivo studies in rats, rabbits, and guinea-pigs to assess effects on collagen- and ionophore-induced thrombocytopenia, bleeding time, and thrombus formation.
Main Results:
- CGS 12970 is a potent and selective inhibitor of human platelet thromboxane synthetase (IC50 = 12 nM).
- It effectively inhibited thromboxane B2 production in vitro, ex vivo, and in vivo without affecting platelet aggregation induced by various agonists.
- CGS 12970 demonstrated unique effects by inhibiting ADP- and Forssman-induced thrombocytopenia, while not impacting Arthus reaction-associated thrombocytopenia or thrombus formation.
Conclusions:
- CGS 12970 is a potent and selective thromboxane synthetase inhibitor with a distinct pharmacological profile.
- Its ability to inhibit specific types of thrombocytopenia, alongside its anti-thromboxane activity, warrants further investigation for potential therapeutic applications.
Abstract:
CGS 12970 is a potent selective inhibitor of human platelet thromboxane synthetase in vitro (IC50 = 12 nM). It is four orders of magnitude less potent as an inhibitor of sheep seminal vesicle cyclooxygenase, bovine aorta prostacyclin synthetase and human leucocyte 15-lipoxygenase. The compound inhibited collagen-induced thromboxane B2 production by human platelets in vitro without an effect on the accompanying platelet aggregation induced by collagen, ADP, platelet activating factor, thrombin, arachidonic acid or the prostaglandin mimetic, U 46619. Administration of CGS 12970 to rats inhibited collagen-induced thromboxane B2 production but had no effect on platelet aggregation ex vivo. It also had no effect on platelet aggregation induced by thrombin or on plasma clotting times. A single oral dose of 1 or 3 mg kg-1 to rabbits inhibited thromboxane B2 production in clotting blood ex vivo for 12 or 24 h respectively. CGS 12970 inhibited thromboxane B2 production in vivo induced by intravenous administration of collagen to rats or calcium ionophore to guinea-pigs. In both cases there was a concomitant elevation of immunoreactive 6-keto-prostaglandin F1 alpha but no effect on the induced thrombocytopenia. As with other thromboxane synthetase inhibitors, CGS 12970 prolonged tail bleeding time in the rat. However, CGS 12970 was not as potent as other thromboxane synthetase inhibitors in this test. In addition to these usual effects of thromboxane synthetase inhibitors, CGS 12970 inhibited the thrombocytopenia induced by the Forssman reaction or ADP administration. In these tests the effect of the compound was of short duration. 8 CGS 12970 had no effect on the thrombocytopenia associated with the Arthus reaction which distinguishes it from cyclo-oxygenase inhibitors. It also had no effect on thrombus formation on a cotton thread in an arteriovenous shunt in the rat.